ARL6IP1 mediates cisplatin-induced apoptosis in CaSki cervical cancer cells

Oncology Reports

Volumn 23, Issue 5, 2010, Pages 1449-1455

  Guo, Fengjie ^a   Li, Yalin ^a   Liu, Yan ^a   Wang, Jiajia ^a   Li, Guancheng ^a  

^a Central South University   (China)

Author keywords

Apoptosis; ARL6IP1; Cervical cancer; Cisplatin

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 6 INTERACTING PROTEIN 1; CASPASE 3; CASPASE 9; CISPLATIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; REGULATOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; UPREGULATION; UTERINE CERVIX CANCER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; FEMALE; HUMANS; MEMBRANE PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

EID: 77950792886     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000783     Document Type: Article

References (35)

1. Zhang Y and Shen X: Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity. Clin Cancer Res 13: 2855-2864, 2007.
2. Liang BC and Ullyatt E: Increased sensitivity to cis- diamminedichloroplatinum induced apoptosis with mitochondrial DNA depletion. Cell Death Differ 5: 694-701, 1998.
3. Pinto AL and Lippard SJ: Binding of the antitumor drug cisdiamminedichloroplatinum (II) (cisplatin) to DNA. Biochim Biophys Acta 780: 167-180, 1985.
4. Kelland LR: New platinum antitumor complexes. Crit Rev Oncol Hematol 15: 191-219, 1993.
5. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri Es and Wang X: Cytochrome C and dATP-dependent formation of Apaf-1/caspase 9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997.
6. Jones NA, Turner J, McIlwrath AJ, Brown R and Dive C: Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak upregulation and the functional status of p53. Mol Pharmacol 53: 819-826, 1998.
7. Henkels KM and Turchi JJ: Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatinresistant and -sensitive human ovarian cancer cell lines. Cancer Res 59: 3077-3083, 1999.
8. Sánchez-Prieto R, Rojas JM, Taya Y and Gutkind S: A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res 60: 2464-2472, 2000.
9. Furuya K, Ozaki T, Hanamoto T, et al: Stabilization of p73 by nuclear IkappaB kinase-alpha mediates cisplatin-induced apoptosis. J Biol Chem 282: 18365-18378, 2007.
10. Coleman AB, Momand J and Kane SE: Basic fibroblast growth factor sensitizes NIH 3T3 cells to apoptosis induced by cisplatin. Mol Pharmacol 57: 324-333, 2000.
11. BenharM, Dalyot I, Engelberg D and Levitzki A: Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogenactivated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 21: 6913-6926, 2001.
12. Mansouri A, Ridgway LD, Korapati AL, et al: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278: 19245-19256, 2003.
13. Chu G: Cellular responses to cisplatin. The roles of DNAbinding proteins and DNA repair. J Biol Chem 269: 787-790, 1994.
14. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542, 1998.
15. Kasimir-Bauer S, OttingerH, Meusers P, et al: In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol 26: 1111-1117, 1998. (Pubitemid 28507285)
16. Kasimir-Bauer S, Beelen D, Flasshove M, et al: Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Exp Hematol 30: 1302-1308, 2002.
17. Ingley E, Williams JH, Walker CE, et al: A novel ADPribosylation like factor (ARL-6), interacts with the proteinconducting channel SEC61beta subunit. FEBS Lett 459: 69-74, 1999.
18. Lui HM, Chen J, Wang L and Naumovski L: ARMER, apoptotic regulator in the membrane of the endoplasmic reticulum, a novel inhibitor of apoptosis. Mol Cancer Res 1: 508-518, 2003.
19. Pettersson M, Bessonova M, Gu HF, Groop LC and Jönsson JI: Characterization, chromosomal localization, and expression during hematopoietic differentiation of the gene encoding Arl6ip, ADP-ribosylation-like factor-6 interacting protein (ARL6). Genomics 68: 351-354, 2000.
20. Daniel NN and Korsmeyer SJ: Cell death: critical control points. Cell 116: 205-219, 2004.
21. Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681, 2005.
22. Griffiths GJ, Dubrez L, Morgan CP, et al: Cell damageinduced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 144: 903-914, 1999.
23. Wei MC, Zong WX, Cheng EH, et al: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730, 2001.
24. Farhana L, Dawson MI and Fontana JA: Apoptosis induction by a novel retinoid-related molecule requires nuclear factorkappaB activation. Cancer Res 65: 4909-4917, 2005.
25. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH and Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239-256, 2002.
26. Kojima H, Endo K, Moriyama H, et al: Abrogation of mitochondrial cytochrome C release and caspase-3 activation in acquired multidrug resistance. J Biol Chem 273: 16647-16650, 1998.
27. Liu X, Li P, Widlak P, et al: The 40-kDa subunit of DNA fragmentation and chromatin condensation during apoptosis. Proc Natl Acad Sci USA 95: 8461-8466, 1998.
28. Righetti SC, Perego P, Carenini N and Zunino F: Cooperation between p53 and p73 in cisplatin-induced apoptosis in ovarian carcinoma cells. Cancer Lett 263: 140-144, 2008.
29. Pabla N, Huang S, Mi QS, Daniel R and Dong Z: ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 283: 6572-6583, 2008.
30. Michaud WA, Nichols AC, Mroz EA, et al: Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 15: 1645-1654, 2009.
31. Huang Z, Lei X, Zhong M, et al: Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. Acta Biochim Biophys Sin (Shanghai) 39: 835-843, 2007.
32. Jones NA, Turner J, McIlwrath AJ, Brown R and Dive C: Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak up-regulation and the functional status of p53. Mol Pharmacol 53: 819-826, 1998.
33. Henkels KM and Turchi JJ: Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatinresistant and -sensitive human ovarian cancer cell lines. Cancer Res 59: 3077-3083, 1999.
34. Chung WH, Boo SH, Chung MK, et al: Proapoptotic effects of NF-kappaB on cisplatin-induced cell death in auditory cell line. Acta Otolaryngol 128: 1063-1070, 2008.
35. Winograd-Katz SE and Levitzki A: Cisplatin induces PKB/Akt activation and p38 (MAPK) phosphorylation of the EGF receptor. Oncogene 25: 7381-7390, 2006.